We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

5 hedge funds and large institutions have $927K invested in XTL Biopharmaceuticals in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 5 → 5 (0)

0% less ownership

Funds ownership: 0.02% → 0.02% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

15% less capital invested

Capital invested by funds: $1.1M → $927K (-$169K)

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$2.86K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$6.15K
Name Holding Trade Value Shares
Change 		Change in
Stake
NC
1
Noked Capital
Israel
$398K – – –
NI
2
Noked Israel
Israel
$398K – – –
Morgan Stanley
3
Morgan Stanley
New York
$72K +$2.86K +325 +4%
Invesco
4
Invesco
Georgia
$52K – – –
UBS Group
5
UBS Group
Switzerland
$7K -$6.15K -700 -44%

XTLB Hedge Fund Activity: Q2 2019 in Review

5 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2019, worth a combined $927K — down 15% from $1.1M a quarter earlier.

Fund positioning in XTLB was balanced in Q2 2019: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $2.86K. The largest seller was UBS Group, cutting an estimated $6.15K.

  • 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $927K of XTL Biopharmaceuticals stock for Q2 2019, down 15% quarter-over-quarter.
  • 0 funds opened new XTL Biopharmaceuticals positions in Q2 2019 and 0 closed out.
  • The largest XTL Biopharmaceuticals buyer in Q2 2019 was Morgan Stanley, an estimated $2.86K added.
  • The largest XTL Biopharmaceuticals seller in Q2 2019 was UBS Group, an estimated $6.15K sold.

Based on aggregated 13F filings for Q2 2019.